If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
==== Local government finance ==== In 1979 the Conservatives were strongly represented in local government, as a result of the unpopularity of the outgoing Labour government. Four of the five council associations were Conservative-controlled. Heseltine was able to persuade them to rein in their spending by 1% each year. Whereas previously overspending councils had received extra rate support grants from Whitehall, after six months Heseltine announced a list of fourteen overspending councils who were to have their grant cut, most of them inner London councils and only one of them, Hammersmith & Fulham, Conservative controlled. The move appeared blatantly political as many of the other 114 overspenders were Conservative councils. Council leaders who came to appeal to Heseltine were often humiliated by being interrogated about their budget, to demonstrate their lack of detailed knowledge, before the council treasurer was allowed to speak. From 1980 to 1981 relations with local government became increasingly confrontational, as Labour made large gains in local elections, with a new generation of council leaders such as Ken Livingstone in London and David Blunkett in Sheffield seeking to generate employment through their councils. Council spending now began to rise again, largely as a result of increases by the GLC, Merseyside and West Midlands councils; whereas Labour votes tended to be poorer and eligible for rate rebates, the burden of higher spending tended to fall on businesses and middle class homeowners.
β-Amanitin (beta-Amanitin) is a cyclic peptide comprising eight amino acids. It is part of a group of toxins called amatoxins, which can be found in several mushrooms belonging to the genus Amanita. Some examples are the death cap (Amanita phalloides) and members of the destroying angel complex, which includes A. virosa and A. bisporigera. Due to the presence of α-Amanitin, β-Amanitin, γ-Amanitin and epsilon-Amanitin these mushrooms are highly lethal to human beings.
Lawsone (2-hydroxy-1,4-naphthoquinone), also known as hennotannic acid, is a red-orange dye present in the leaves of the henna plant (Lawsonia inermis), for which it is named, as well as in the common walnut (Juglans regia) and water hyacinth (Pontederia crassipes). Humans have used henna extracts containing lawsone as hair and skin dyes for more than 5,000 years. Lawsone reacts chemically with the protein keratin in skin and hair via a Michael addition reaction, resulting in a strong permanent stain that lasts until the skin or hair is shed. Darker colored staining is due to more lawsone–keratin interactions occurring, which evidently break down as the concentration of lawsone decreases and the tattoo fades. Lawsone strongly absorbs UV light, and aqueous extracts can be effective sunless tanning agents and sunscreens. Lawsone is a 1,4-naphthoquinone derivative, an analog of hydroxyquinone containing one additional ring. Lawsone isolation from Lawsonia inermis can be difficult due to its easily biodegradable nature. Isolation involves four steps:
Prusiner of California named the prion, and thought that the protein did not require DNA to be made; the Institute of Molecular Systems Biology of ETH Zurich, and Charles Weiss mann, who looked for a section of mRNA that could make the protein, and in 1985 found a possible section of DNA; husband and wife, Harry Baker and Ros Ridley of the MRC in London discovered in 1989 that a genetic mutation could cause the prion to be made; seventeen possible genetic mutations were found in total in the UK; children treated with human growth hormone were found, in May 1985, to have CJD; Michael Preece of the UCL Great Ormond Street Institute of Child Health in London; more cases were found in France in 1992; scrapie in sheep; remains of sheep, in cattle feed caused BSE, which was discovered in 1986; Ray Bradley, head of BSE research at the Central Veterinary Laboratory; Graham Medley, a disease modeller at Imperial College, who looked at other modes of possible transmission, than contaminated animal feed; James Kirkwood, of the Institute of Zoology in London, and infection in the greater kudu; Gordon Hunter, veterinary researcher; Hamish Chalmers of Redesdale in Northumberland, and scrapie-resistant Swaledale sheep, which were bred at the Institute for Research on Animal Diseases (now the Pirbright Institute) at Compton, Berkshire; the amyloid beta protein of dementia, and research on marmosets. Narrated by Libby Purves, directed by John Bird, produced by Mike Johnstone, made by Langham Productions
== Work == Ranganathan's special passion was reproducing natural biochemical processes in the laboratory. She created a protocol which achieved the autonomous reproduction of imidazole, an ingredient of histadine and histamine with pharmaceutical importance. She also developed a working simulation of the urea cycle. As her career developed, she became a specialist in designing proteins to hold a wide variety of different conformations and designing nanostructures using self-assembling peptides.
Sources: en.wikipedia.org
==== Non-synthesizers ==== Some mammals have lost the ability to synthesize vitamin C, including simians and tarsiers, which together make up one of two major primate suborders, Haplorhini. This group includes humans. The other more primitive primates (Strepsirrhini) have the ability to make vitamin C. Synthesis does not occur in some species in the rodent family Caviidae, which includes guinea pigs and capybaras, but does occur in other rodents, including rats and mice. Synthesis does not occur in most bat species, but there are at least two species, frugivorous bat Rousettus leschenaultii and insectivorous bat Hipposideros armiger, that retain (or regained) their ability of vitamin C production. A number of species of passerine birds also do not synthesize, but not all of them, and those that do not are not clearly related; it has been proposed that the ability was lost separately a number of times in birds. In particular, the ability to synthesize vitamin C is presumed to have been lost and then later re-acquired in at least two cases. The ability to synthesize vitamin C has also been lost in about 96% of extant fish (the teleosts). Schistosomes (parasitic flatworms) cannot synthesize vitamin C and require it from their hosts in order to produce eggs; in both guinea pigs and in mice genetically engineered to be non-synthesizers, vitamin C deficiency prevents schistosomes from reproducing. In mice, it has additionally been found that vitamin C deficiency (even intermittent) prevents schistosomes from causing disease.
=== Primary glaucoma and its variants === Primary glaucoma (H40.1-H40.2) includes primary open-angle glaucoma (chronic open-angle, chronic simple, glaucoma simplex), which can be high-tension or low-tension, and primary angle closure glaucoma (primary closed-angle, narrow-angle, pupil-block, acute congestive), which can manifest as acute, chronic, intermittent, or superimposed on chronic open-angle closure glaucoma (also called "combined mechanism" glaucoma). Other variants of primary glaucoma include:
== Classification == There are two typing systems for OI in modern use. The first, created by David Sillence in 1979, classifies patients into four types, or syndromes, according to their clinical presentation, without taking into account the genetic cause of their disease. The second system expands on the Sillence model, but assigns new numbered types genetically as they are found. Therefore, people with OI can be described as having both a clinical type and a genetic type, which may or may not be equivalent. Type I is the most common, and 90% of cases result from mutations to either COL1A1 or COL1A2. Symptoms vary widely between types, as well as vary from person to person, even in the same family. As of 2021, 21 types of OI have been defined:
=== A mature bone matrix === In order to mimic a mature bone matrix, self-assembled fibrils can be used to align a given mineral matrix. This is accomplished using a self-assembling molecule with a hydrophobic alkyl tail and a hydrophilic oligopeptide head. These molecules form micellar structures in situ, and disulfide bridges at low pH, leading to the formation and crystallization of 200 kDa polymeric nanofibrils. The mineral matrix ultimately interacts with the synthetic fibril via a phosphoserine residue which results in mineral nucleation and growth.
Bone is constantly being created and replaced in a process known as remodeling. This ongoing turnover of bone is a process of resorption followed by replacement of bone with little change in shape. This is accomplished through osteoblasts and osteoclasts. Cells are stimulated by a variety of signals, and together referred to as a remodeling unit. Approximately 10% of the skeletal mass of an adult is remodelled each year. The purpose of remodeling is to regulate calcium homeostasis, repair microdamaged bones from everyday stress, and to shape the skeleton during growth. Repeated stress, such as weight-bearing exercise or bone healing, results in the bone thickening at the points of maximum stress (Wolff's law). It has been hypothesized that this is a result of bone's piezoelectric properties, which cause bone to generate small electrical potentials under stress. The action of osteoblasts and osteoclasts are controlled by a number of chemical enzymes that either promote or inhibit the activity of the bone remodeling cells, controlling the rate at which bone is made, destroyed, or changed in shape. The cells also use paracrine signalling to control the activity of each other. For example, the rate at which osteoclasts resorb bone is inhibited by calcitonin and osteoprotegerin. Calcitonin is produced by parafollicular cells in the thyroid gland, and can bind to receptors on osteoclasts to directly inhibit osteoclast activity. Osteoprotegerin is secreted by osteoblasts and is able to bind RANK-L, inhibiting osteoclast stimulation.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.